title: Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers.
abstract: (18)F-CP-18, or (18S,21S,24S,27S,30S)-27-(2-carboxyethyl)-21-(carboxymethyl)-30-((2S,3R,4R,5R,6S)-6-((2-(4-(3-F18-fluoropropyl)-1H-1,2,3-triazol-1-yl)acetamido)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxamido)-24-isopropyl-18-methyl-17,20,23,26,29-pentaoxo-4,7,10,13-tetraoxa-16,19,22,25,28-pentaazadotriacontane-1,32-dioic acid, is being evaluated as a tissue apoptosis marker for PET imaging. The purpose of this study was to determine the biodistribution and estimate the normal-organ radiation-absorbed doses and effective dose from (18)F-CP-18.
  
  
  METHODS
  Successive whole-body PET/CT scans were obtained at approximately 7, 45, 90, 130, and 170 min after intravenous injection of (18)F-CP-18 in 7 healthy human volunteers. Blood samples and urine were collected between the PET/CT scans, and the biostability of (18)F-CP-18 was assessed using high-performance liquid chromatography. The PET scans were analyzed to determine the radiotracer uptake in different organs. OLINDA/EXM software was used to calculate human radiation doses based on the biodistribution of the tracer.
  
  
  RESULTS
  (18)F-CP-18 was 54% intact in human blood at 135 min after injection. The tracer cleared rapidly from the blood pool with a half-life of approximately 30 min. Relatively high (18)F-CP-18 uptake was observed in the kidneys and bladder, with diffuse uptake in the liver and heart. The mean standardized uptake values (SUVs) in the bladder, kidneys, heart, and liver at around 50 min after injection were approximately 65, 6, 1.5, and 1.5, respectively. The calculated effective dose was 38 ± 4 μSv/MBq, with the urinary bladder wall having the highest absorbed dose at 536 ± 61 μGy/MBq using a 4.8-h bladder-voiding interval for the male phantom. For a 1-h voiding interval, these doses were reduced to 15 ± 2 μSv/MBq and 142 ± 15 μGy/MBq, respectively. For a typical injected activity of 555 MBq, the effective dose would be 21.1 ± 2.2 mSv for the 4.8-h interval, reduced to 8.3 ± 1.1 mSv for the 1-h interval.
  
  
  CONCLUSIONS
  (18)F-CP-18 cleared rapidly through the renal system. The urinary bladder wall received the highest radiation dose and was deemed the critical organ. Both the effective dose and the bladder dose can be reduced by frequent voiding. From the radiation dosimetry perspective, the apoptosis imaging agent (18)F-CP-18 is suitable for human use.
authors.affiliation: Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
authors.forename: Mohan
authors.initials: M
authors.lastname: Doss
authors.forename: Hartmuth C
authors.initials: HC
authors.lastname: Kolb
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Walsh
authors.forename: Vani
authors.initials: V
authors.lastname: Mocharla
authors.forename: Hong
authors.initials: H
authors.lastname: Fan
authors.forename: Ashok
authors.initials: A
authors.lastname: Chaudhary
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Zhu
authors.forename: R Katherine
authors.initials: RK
authors.lastname: Alpaugh
authors.forename: Miriam N
authors.initials: MN
authors.lastname: Lango
authors.forename: Jian Q
authors.initials: JQ
authors.lastname: Yu
mesh_terms: D000328:Adult; D017209:Apoptosis; D005260:Female; D006020:Glycopeptides / Q000493:pharmacokinetics*; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D011874:Radiometry; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed; D014230:Triazoles / Q000493:pharmacokinetics*
chemical_list: C586095:CP-18 compound; D006020:Glycopeptides; D014230:Triazoles
keywords: 18F-CP-18; PET; apoptosis marker; biodistribution; internal dosimetry